Subject Withdrawal. Data Provider acknowledges that subjects may withdraw their informed consent to the Processing of Personal Data at any time. Data Provider shall promptly notify Data Recipient of any such withdrawal upon which the Data Recipient will immediately discontinue use of the subject’s Personal Data.
Subject Withdrawal. If a subject does not report for a scheduled follow-up visit, Principal Investigator shall contact the subject within ten (10) days after the date of the scheduled visit regarding the failure to keep the appointment. If a subject withdraws from the Clinical Trial, Principal Investigator shall follow up with the subject in person or by telephone (if possible), otherwise by certified mail, to determine the reason for the discontinuance and complete the termination form.
Subject Withdrawal. If a Subject does not report for a scheduled follow-up visit Investigator shall contact the Subject within ten
Subject Withdrawal. Subjects may withdraw from the trial at any time and for any reason. Additionally, the investigator must discontinue participation for any subject who: · Experiences an adverse event that, based on the investigator’s medical judgment, would jeopardize the subject’s well being or prevent the safe completion of the study; · Becomes pregnant; · Requires other medical treatment that is excluded by the protocol; · Has their treatment unblinded by the investigator; · Is unwilling to comply with the provisions of the protocol. Investigators must discontinue trial participation for all subjects if the Sponsor terminates the trial. Evaluations that would normally be performed upon trial completion should be made for all subjects who exit the trial prematurely. For subjects who have received ***, this includes obtaining appropriate samples for laboratory testing, and performing a physical examination (including ECG). Additionally, for all subjects who discontinue trial participation prematurely, investigators should make all reasonable attempts to schedule a clinic visit at week 28 to make a final weight assessment. *** INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. If a subject does not return for a scheduled visit, every effort should be made to contact the subject. In any circumstance, every effort should be made to document subject outcome, if possible. The investigator should *** If the subject withdraws from the trial and also withdraws consent for disclosure of future information, ***. ***.
Subject Withdrawal. Subjects may withdraw from the trial at any time and for any reason. Additionally, the subject may be withdrawn because of: · Adverse event; · Subject lost to follow-up; · Requirement for other medical treatment excluded by the protocol; · Lack of compliance with the provisions of the protocol; · Treatment unblinded by investigator; · Pregnancy; · Lack of efficacy; · Termination of trial. Withdrawn subjects will not be replaced.
Subject Withdrawal. Subjects may withdraw from the trial at any time and for any reason. Additionally, the subject may be withdrawn because of: · Adverse event; · Subject lost to follow-up; *** INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. · Requirement for other medical treatment excluded by the protocol; · Lack of compliance with the provisions of the protocol; · Treatment unblinded by investigator; · Pregnancy; · Lack of efficacy; · Termination of trial. Withdrawn subjects will not be replaced.
